Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02426684 · ClinicalTrials.gov registry record · Phase 1
Ides in Highly Sensitized (HS) Patients Awaiting Kidney Transplantation
A Phase 1 study, sponsored by Cedars-Sinai Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT02426684 is a Phase 1 study that has completed, run by Cedars-Sinai Medical Center. The registered enrollment target is 17 participants.
The verdict
NCT02426684, a Phase 1 study, has completed, sponsored by Cedars-Sinai Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
This is a single center phase I/II open label, exploratory study assessing safety and efficacy of IdeS® (Hansa Medical, Lund, Sweden) given immediately prior to kidney transplantation. We hope that IdeS® will help eliminate DSAs in HS patients who are DSA+ and flow cytometry (FCMX) crossmatch + at time of transplant. We plan to enroll a total of 20 patients. Patients will be followed for 6 months post administration of IdeS®.
Interventions
- DRUG IdeS® (Imlifidase)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2015-06-16 |
| Est. Completion | 2017-11-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02426684
The ClinicalTrials.gov registry entry for NCT02426684 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cedars-Sinai Medical Center, which has 339 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which IdeS® (Imlifidase) is the first listed.
NCT02426684 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02426684 about?
NCT02426684 is a clinical study titled "Ides in Highly Sensitized (HS) Patients Awaiting Kidney Transplantation". This is a single center phase I/II open label, exploratory study assessing safety and efficacy of IdeS® (Hansa Medical, Lund, Sweden) given immediately prior to kidney transplantation. We hope that IdeS® will help eliminate DSAs in HS patients who are DSA+ and flow cytometry (FCMX) crossmatch + at t...
What is the current status of trial NCT02426684?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2015-06-16. Estimated completion is 2017-11-10.
What interventions are being tested in trial NCT02426684?
The interventions under investigation include: IdeS® (Imlifidase) (DRUG).
Who is sponsoring clinical trial NCT02426684?
This trial is sponsored by Cedars-Sinai Medical Center, which has 339 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.